Long-Term Benefit from Adjuvant Tamoxifen in Luminal A and Luminal B Breast Cancer Patients

被引：0
|
作者：
Dar, Huma
Johansson, Annelie
Nordenskjold, Anna
Perez-Tenorio, Gizeh
Yau, Christina
Benz, Christopher C.
Esserman, Laura J.
Nordenskjold, Bo
Stal, Olle
Fornander, Tommy
Lindstrom, Linda S.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P2-03-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-03-04
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
    Anna Nordenskjöld
    Helena Fohlin
    Tommy Fornander
    Britta Löfdahl
    Lambert Skoog
    Olle Stål
    Breast Cancer Research and Treatment, 2016, 160 : 313 - 322
  • [22] Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
    Nordenskjold, Anna
    Fohlin, Helena
    Fornander, Tommy
    Lofdahl, Britta
    Skoog, Lambert
    Stal, Olle
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 160 (02) : 313 - 322
  • [23] Luminal A and Luminal B subtypes in patients with breast cancer 65 years of age and older
    Konigsberg, Robert
    Pfeller, Georg
    Hammerschmid, Nicols
    Klement, Tatjana
    Dittrich, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [24] Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients
    Atif Ali Hashmi
    Saher Aijaz
    Saadia Mehmood Khan
    Raeesa Mahboob
    Muhammad Irfan
    Narisa Iftikhar Zafar
    Mariam Nisar
    Maham Siddiqui
    Muhammad Muzzammil Edhi
    Naveen Faridi
    Amir Khan
    World Journal of Surgical Oncology, 16
  • [25] Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer
    Nataliya Babyshkina
    Sergey Vtorushin
    Tatyana Dronova
    Stanislav Patalyak
    Elena Slonimskaya
    Julia Kzhyshkowska
    Nadejda Cherdyntseva
    Evgeny Choynzonov
    Clinical and Experimental Medicine, 2019, 19 : 547 - 556
  • [26] Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer
    Babyshkina, Nataliya
    Vtorushin, Sergey
    Dronova, Tatyana
    Patalyak, Stanislav
    Slonimskaya, Elena
    Kzhyshkowska, Julia
    Cherdyntseva, Nadejda
    Choynzonov, Evgeny
    CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 19 (04) : 547 - 556
  • [27] Anastrozole and Tamoxifen Impact on IgG Glycome Composition Dynamics in Luminal A and Luminal B Breast Cancers
    Rapcan, Borna
    Fancovic, Matko
    Pribic, Tea
    Kirac, Iva
    Gace, Mihaela
    Vuckovic, Frano
    Lauc, Gordan
    ANTIBODIES, 2024, 13 (01)
  • [28] LONG-TERM ADJUVANT TAMOXIFEN THERAPY FOR BREAST-CANCER - THE PRELUDE TO PREVENTION
    JORDAN, VC
    CANCER TREATMENT REVIEWS, 1990, 17 (01) : 15 - 36
  • [29] Progesterone receptor positivity is an independent predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer
    Fohlin, H.
    Nordenskjold, A.
    Fornander, T.
    Lofdahl, B.
    Skoog, L.
    Stal, O.
    CANCER RESEARCH, 2016, 76
  • [30] Adjuvant treatment for luminal breast cancer of intermediate prognosis
    Dhib, Donia
    Mejri, Nesrine
    Berrazaga, Yosra
    Rachdi, Haifa
    Saadi, Myriam
    Daoud, Nouha
    Hammouda, Boussen
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (SUPPL_4) : A96 - A97
12345